# Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Moderate to Severe Active SLE Clinical Research

> **NCT06711146** · EARLY_PHASE1 · RECRUITING · sponsor: **Zhejiang University** · enrollment: 36 (estimated)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **DRUG:** Metabolically Armed CD19 CAR-T cells

## Key facts

- **NCT ID:** NCT06711146
- **Lead sponsor:** Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-24
- **Primary completion:** 2026-12-01
- **Final completion:** 2027-04-05
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-03-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06711146

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06711146, "Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Moderate to Severe Active SLE Clinical Research". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06711146. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*